A patch that delivers the drug rotigone, which helps treat the symptoms of Parkinson's disease, has been proved to be more popular among sufferers than an oral therapy.
Studies were presented last week at the World Parkinson Congress which suggested that the use of the patch will cause no significant problems, reports United Press International (UPI).
Rotigone mimics the action of dopamine by stimulating the part of the brain that makes it think it is receiving the hormone.
It is anticipated that the patch system will avoid the impracticality of many patients who suffer from the severe form of the illness having to administer their own medicine.
The once-daily patch is also expected to be a welcome addition for caregivers, as patients often require the administration of various other orally-taken drugs.
"This is something we have never seen in drugs that are given orally. It is a huge advantage afforded by this patch-delivered treatment," Nir Giladi, director of movement disorders at Tel Aviv Medical Centre and professor of neurology at Tel Aviv University, told UPI.
The NeuPro patch had been designed as an additional treatment to the traditional drug levodopa, which is used to aid sufferers.